This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Corcept Therapeutics Faces...
Regulatory securities fraud lawsuit

Corcept Therapeutics Faces Securities Fraud Lawsuit

Analysis based on 31 articles · First reported Feb 03, 2026 · Last updated Mar 10, 2026

Sentiment
-20
Attention
2
Articles
31
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the regulatory setback for Corcept Therapeutics' drug relacorilant, leading to a significant drop in its stock price. The subsequent securities fraud lawsuit against Corcept Therapeutics further adds to investor uncertainty and potential financial losses for shareholders.

Pharmaceuticals Biotechnology Legal Services
Event Summary

Corcept Therapeutics Incorporated is facing a securities fraud class action lawsuit after the United States===Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on December 31, 2025, declining to approve the company's New Drug Application (NDA) for relacorilant. The FDA cited concerns about the adequacy of the clinical development program and the need for additional evidence of effectiveness. This news caused Corcept Therapeutics' stock price to fall by over 50% on December 31, 2025. An updated CRL on January 30, 2026, further revealed that the FDA had previously informed Corcept Therapeutics of its concerns regarding the trial design. The lawsuit alleges that Corcept Therapeutics made materially false and/or misleading statements and failed to disclose these adverse facts to investors.

Key Actions
95 Corcept Therapeutics stock price fell by 50.42%
90 United States===Food and Drug Administration issued Complete Response Letter for relacorilant NDA Corcept Therapeutics
85 Howard G. Smith filed a class action lawsuit Corcept Therapeutics
Entities Involved
stock
Corcept Therapeutics
Corcept Therapeutics faces a securities fraud lawsuit after the United States===Food and Drug Administration declined to approve its New Drug Application for relacorilant. The company's stock price fell significantly following the news, indicating a negative market reaction to the regulatory setback and subsequent legal action.
Importance 100 Sentiment -80
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration issued a Complete Response Letter, declining to approve Corcept Therapeutics' New Drug Application for relacorilant due to concerns about effectiveness. This regulatory decision directly triggered the stock price drop and the subsequent lawsuit against Corcept Therapeutics.
Importance 80 Sentiment 0
per
Howard G. Smith
Howard G. Smith's law offices are representing investors in a class action lawsuit against Corcept Therapeutics, alleging securities fraud. This action aims to recover losses for investors who purchased Corcept Therapeutics common stock during the specified Class Period.
Importance 60 Sentiment 50
exch
Nasdaq
Corcept Therapeutics is listed on Nasdaq, and its stock price decline was observed on this exchange.
Importance 10 Sentiment 0
Relationships
Corcept Therapeutics related ↔ United States===Food and Drug Administration
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.